Antiepileptics and bone health

Phytoflavonoids: Antiepileptics for the Future

Epilepsy has become second most common neurological disorder affecting 70 million people worldwide. Several shortcomings appeared with the use of conventional antiepileptic drugs (AEDs) like, inadequate seizure control, side effects, cost, potentiation of epilepsy-induced co-morbidities, etc., which limit their use as comprehensive therapy. Phytoflavonoids in this regard have been observed to b...

Antiepileptics and suicidal thoughts and behaviour

Interactions between antiepileptics and second-generation antipsychotics.

INTRODUCTION Pharmacokinetic and pharmacodynamic drug interactions (DIs) can occur between antiepileptics (AEDs) and second-generation antipsychotics (SGAPs). Some AED and SGAP pharmacodynamic mechanisms are poorly understood. AED-SGAP combinations are used for treating comorbid illnesses or increasing efficacy, particularly in bipolar disorder. AREAS COVERED This article provides a comprehen...

Bone deficit and bone health.

Pharmacokinetic and pharmacodynamic interactions between antiepileptics and antidepressants.

INTRODUCTION Antiepileptic-antidepressant combinations are frequently used by clinicians; their pharmacokinetic (PK) and pharmacodynamic (PD) drug interactions (DIs) have not been well studied but are frequently likely to be clinically relevant. AREAS COVERED This article provides a comprehensive review of PK DIs between antiepileptics and antidepressants. In the absence of PD DI studies, PD ...